Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.38 |
| ▸ | TNF | P01375 | 2/20 | 0.38 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.36 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8227926 | 0.92 | AOC3 (0.44) | ITGB3ITGA2BAOC3 | |
| SCHEMBL13201367 | 0.90 | ADAM17 (0.43) | TNFADAM17 | |
| SCHEMBL5955645 | 0.90 | ADAM17 (0.43) | TNFADAM17 | |
| SCHEMBL13201492 | 0.87 | DRD2 (0.41) | DRD2DRD4ITGB3ITGA2BTNF | |
| SCHEMBL13201500 | 0.83 | ADAM17 (0.41) | DRD2DRD4ITGB3ITGA2BTNF | |
| SCHEMBL10112007 | 0.82 | ADAM17 (0.43) | TNFADAM17 | |
| SCHEMBL16311333 | 0.82 | ADAM17 (0.43) | TNFADAM17 | |
| SCHEMBL13201491 | 0.81 | TNF (0.55) | DRD2DRD4TNFADAM17HTR2C | |
| SCHEMBL13201451 | 0.81 | TNF (0.35) | TNFADAM17 | |
| SCHEMBL13201489 | 0.80 | AOC3 (0.40) | ITGB3ITGA2BAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772263-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772263-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090156586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-7524842-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | DRD2 4859/4885DRD4 4855/4885ITGB3 1884/4885 |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | DRD2 4859/4885DRD4 4855/4885ITGB3 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.